Enzo Biochem has announced that preliminary voting results from the Special Meeting of Shareholders indicate that the Asset Sale Proposal has been approved by the majority of Enzo’s outstanding common stock. Pending final results, this approval allows Enzo to proceed with the sale of its Clinical Labs division’s operating assets and the assignment of certain liabilities. Enzo’s CEO, Hamid Erfanian, expressed gratitude for the shareholders’ support and stated that the company looks forward to advancing its “focused return” initiative and maximizing shareholder value in the next phase.
Enzo Biochem, Inc. (NYSE:ENZ), announced today that the preliminary voting results from the Inspector of Election at today’s Special Meeting of the Shareholders indicate that the Asset Sale Proposal was approved by the affirmative vote of a majority of Enzo’s outstanding common stock. Pending final results of the vote, Enzo will have obtained shareholder approval and met all regulatory requirements for closing the sale of substantially all of the operating assets and assignment of certain liabilities of Enzo’s Clinical Labs division.
“We are grateful for the continuous support from our shareholders, many of whom have placed their trust in the Company for many years,” said Hamid Erfanian, CEO of Enzo Biochem. “With the support of our shareholders for the asset sale, we look forward to advancing the Company’s “focused return” initiative and maximizing shareholder value in its next phase.”
Source: BioSpace
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
